College of Psychiatric and Neurologic Pharmacists Position Statement: Psychiatric Pharmacist Integration into Medical Home Model
College of Psychiatric and Neurologic Pharmacists Position Statement: Psychiatric Pharmacist Integration into Medical Home Model
The 2012-2013 CPNP Psychiatric Pharmacotherapy Review Course (ACPE Only) includes the following:
AAPP has developed an array of resources to help directly inform patients and caregivers. Clinicians are encouraged to print and distribute these resources as they see fit. AAPP members can access additional formats and clinical resources via the Medication Database.
No summary available
No summary available
One of the primary purposes of CPNP as an association is to advance the pharmacy profession. Government and Professional Affairs is an important way for us to work together to do that.
Thanks to all 2025 donors.
This white paper offers practical recommendations for health care leaders, policymakers, peer support programs, and individuals and families, and covers workforce development, program infrastructure, outreach, outcome measurement and policy reform.
AAPP is exploring the impact of AI on the role of psychiatric pharmacists. To better understand the various perspectives, we will meet in Zoom on April 7 with members holding the opinions that (1) AI is an opportunity for BCPPs to lead, (2) AI will have minimal impact on patient care by BCPPs, and (3) AI is an existential threat to the specialty.
No summary available
A large, new study found that the stimulant methylphenidate, such as the drugs Ritalin and Concerta, may lower the risk of psychosis when prescribed to younger children with ADHD.
A growing proportion of antipsychotic prescriptions for older adults were written by nonphysician clinicians, reflecting shifts in the mental health care workforce and prescribing practices, cross-sectional data showed. From 2013 to 2023, antipsychotic prescription claims for Medicare Part D beneficiaries written by psychiatrists and primary care physicians (PCPs) declined annually by 3.2% and 2.6%, respectively (P0.001 for both).
Between 4.9 and 10.1 million people could lose Medicaid coverage in 2028 as the result of new work requirements and more frequent eligibility checks.
AAPP joined the American Society of Addiction Medicine, ASHP, and other healthcare associations in a letter to Representative Houchin encouraging revisions to H.R. 5629 which would increase overdoses and reduce access to evidence-based OUD care, especially in rural areas. We argue that, if enacted as currently drafted, the bill would result in more opioid overdoses, because fewer people would get methadone treatment for OUD, with no improvement in safety for our communities.
Lessons from 10 FORE Grantees that have expanded access to prevention, treatment, and recovery supports in rural communities.
This Recovery Research Institute summary highlights a cross-sectional analysis of National Survey on Drug Use and Health data showing.
The current evidence base is not sufficient to support the use of cannabis for the treatment of mental health conditions and demonstrates substantial risks of adverse effects.
In this study, the volume of patients treated with buprenorphine increased after private equity acquisition, with minimal changes in the payer mix among these patients.
The colorful packaging and fruity flavors that make nicotine pouches appealing to adults also make them tempting — and dangerous — for kids.
The Department of Health and Human Services Office for Civil Rights announced a new civil enforcement program to protect the confidentiality of SUD records for individuals under 42 CFR Part 2. This initiative allows for resolution agreements, monetary settlements, and corrective action plans aligned with HIPAA enforcement standards to address noncompliance and breach notifications.
These findings emphasize the role of social support and integrated treatment in fostering recovery and inform the design of individualized university recovery programs.
PolySU was pervasive among young people entering AOD treatment.
The primary and key secondary outcomes were illicit opioid abstinence during pregnancy and the postpartum period, respectively, defined as the proportion of weekly collected urine samples negative for illicit opioids.